Country: United Kingdom
Language: English
Source: VMD (Veterinary Medicines Directorate)
Marbofloxacin
CP Pharma Handelsgesellschaft mbH
QJ01MA93
Marbofloxacin
Solution for injection
POM-V - Prescription Only Medicine – Veterinarian
Cattle, Pigs
Antimicrobial
Expired
2013-02-15
Revised: January 2015 AN. 01099/2014 Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbosol 20 mg/ml solution for injection for calves and piglets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ML SOLUTION FOR INJECTION CONTAINS: Active substance: Marbofloxacin 20 mg Excipients: Metacresol 2 mg Monothioglycerol 0.50 mg For full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection. Clear, yellow solution. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle (pre-ruminating calves), piglets 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES PRE-RUMINATING CALVES: For treatment and prevention of respiratory infections caused by marbofloxacin susceptible _Mannheimia haemolytica_ and _Pasteurella multocida_ strains, where the presence of the disease has been established in the group. PIGLETS: For the treatment of respiratory infections caused by marbofloxacin susceptible _ Actinobacillus pleuropneumoniae_, Mycoplasma _ hyopneumoniae _ and _Pasteurella multocida_ strains. 4.3 CONTRAINDICATIONS Do not use in case of bacterial infections with resistance to other (fluoro) quinolones (cross resistance). Do not use in case of hypersensitivity to the active substance or to any of the excipients. Revised: January 2015 AN. 01099/2014 Page 2 of 5 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None 4.5 SPECIAL PRECAUTIONS FOR USE i. Special precautions for use in animals Official and local antimicrobial policies should be taken into account when the product is used. Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials. Whenever possible, fluoroquinolones should only be used based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential f Read the complete document